Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results

Neurology

Volumn 56, Issue 11, 2001, Pages 1505-1513

  Li, David K B ^a   Zhao, G J ^a   Paty, D W ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; NEUTRALIZING ANTIBODY;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; TREATMENT OUTCOME;

EID: 0035849494     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.56.11.1505     Document Type: Article

References (18)

1. PRISMS 4-year results: Evidence of clinical dose effect of interferon beta-1a in relapsing MS
2. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
3. Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis
4. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis
5. Randomized double-blind placebo-controlled study of interferon-beta-1a in relapsing/remitting multiple sclerosis
6. Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon-β1a in relapsing-remitting multiple sclerosis
7. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis
8. Effect of interferon-β1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: Results of a European multicenter, randomized, double-blind, placebo-controlled trial
9. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results
10. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
11. Lesion load reproducibility and statistical sensitivity of clinical trials in multiple sclerosis
12. The comparison of more than two treatments
13. Interferon beta-1b in secondary progressive MS: Clinical and MRI results of a 3-year randomized controlled trial
14. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis
15. Longitudinal MRI in multiple sclerosis: Correlation between disability and lesion burden
16. Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis
17. Quantitative brain MRI lesion load predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis
18. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: A meta-analysis